USA flag logo/image

An Official Website of the United States Government

PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

Award Information

Agency:
Department of Defense 		Branch:
Army 		Award ID:
81534 		Program Year/Program:
2007 / SBIR
Agency Tracking Number:
A072-142-0602 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
PLX PHARMA, INC.
8285 EL RIO HOUSTON, TX 77054-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2007
Title: PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs
Agency / Branch: DOD / ARMY
Contract: W81XWH-08-C-0025
Award Amount: $69,997.00
 

Abstract:

Contrasting in vitro and in vivo systems will be used to evaluate the anti-inflammatory/analgesic activity and side-effects of a family of phosphatidylcholine (PC) - associated NSAIDs. Previous studies indicate that PC-NSAIDs have equivalent and/or enhanced therapeutic activity while GI ulceration/bleeding is remarkably reduced. Dr. Susan Carlton's lab will measure the effect of our test NSAIDs (PC-NSAID vs unmodified NSAIDs) on calcium signaling of rodent dorsal root ganglia cells in response inflammatory mediators. Her lab also will electrophysiologically measure the effect of test NSAIDs on nociceptive C-fiber activity of a rodent skin-nerve preparation. Dr. Catherine Ambrose will investigate the effect of the test NSAIDs on growth/apoptosis of human osteoblasts in culture. During the Option period, Dr. Lenard Lichtenberger's lab will utilize a rodent model of adjuvant-induced joint inflammation that provides information on the anti-inflammatory/analgesic activity of the test NSAIDs and their ability to induce GI ulceration/bleeding. The synovial fluid eicosanoids will be measured by HPLC/MS. Dr. Carlton also will evaluate the anti-inflammatory/analgesic activity of PC-NSAIDs using a rodent hindlimb incision model. In Phase II we plan to expand our in vivo evaluation of PC-NSAIDs using an array of rodent model systems available in the labs of the Co-Investigators.

Principal Investigator:

Upendra Marathi
Senior Vice President
7138421249
marathi@plxpharma.com

Business Contact:

Ron Zimmerman
President
7138421249
ron.zimmerman@plxpharma.com
Small Business Information at Submission:

PLX PHARMA, INC.
8285 EL RIO, SUITE 130 HOUSTON, TX 77054

EIN/Tax ID: 141857610
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No